Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 25 versus ORETICYL 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 25 versus ORETICYL 25.
CAPOZIDE 50/25 vs ORETICYL 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive NaCl cotransporter, increasing excretion of sodium, chloride, and water. Deserpidine depletes catecholamines from peripheral sympathetic nerve endings by binding to the vesicular monoamine transporter, reducing vascular resistance and heart rate.
One tablet (captopril 50 mg / hydrochlorothiazide 25 mg) orally once daily; may increase to two tablets daily if needed.
Hydrochlorothiazide 25 mg orally once daily; may increase to 50 mg daily if needed.
None Documented
None Documented
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: dosing interval typically 12-24 hours.
2.5 hours; in renal impairment may extend to 8–15 hours.
Captopril: 95% renal (primarily unchanged). Hydrochlorothiazide: 95% renal (unchanged).
Primarily renal (95% unchanged); minimal biliary (<5%).
Category C
Category C
ACE Inhibitor/Diuretic Combination
Diuretic Combination